Authors: Tot Bui, Jeff Stevenson, John Hoekman, Shanrong Zhang, Kenneth Maravilla, Rodney J. Y. Ho
DOI: 10.1371/journal.pone.0013082
Abstract Summary
Researchers developed gadolinium-lipid nanoparticles (Gd-LNP) that achieve 33-fold higher MRI contrast sensitivity than current agents, requiring only 3% of the standard dose. These nanoparticles clear through bile rather than kidneys, potentially eliminating Nephrogenic Systemic Fibrosis risk in patients with renal impairment—a major safety concern with existing contrast agents.
Why Brain? ðŸ§
New gadolinium nanoparticles deliver 33-fold better MRI contrast at 97% lower dose, avoid kidney clearance, and reduce toxicity risk in patients with renal impairment.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
